SCHEMBL353264

SCHEMBL353264

O=C(NC1=CC(=O)C2OC2C1=O)c1ccncc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 1/20 0.46
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39
HPGD P15428 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4D Q6B0I6 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
KCNMA1 Q12791 2/20 0.33
HSD17B10 Q99714 2/20 0.33
ROCK2 O75116 2/20 0.33
ROCK1 Q13464 2/20 0.33
HTT P42858 3/20 0.32
NAMPT P43490 1/20 0.32
LMNA P02545 3/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CYP11B2 P19099 2/20 0.31
CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5474018 0.83 LMNA (0.47) P2RX1ALDH1A1KDM4EMEN1HPGD
SCHEMBL13014189 0.83 LMNA (0.47) P2RX1ALDH1A1KDM4EMEN1HPGD
SCHEMBL353219 0.79 PRKCI (0.35) ALDH1A1KDM4EMEN1HPGDKMT2A
SCHEMBL115015 0.75 P2RX1 (0.44) P2RX1MEN1KMT2ANPC1RAB9A
SCHEMBL13014489 0.74 KMT2A (0.50) ALDH1A1KDM4EMEN1HPGDKMT2A
SCHEMBL17439049 0.68 KDM5A (0.48) P2RX1ALDH1A1KDM4EMEN1HPGD
SCHEMBL4983594 0.66 KDM4E (0.53) P2RX1ALDH1A1KDM4EMEN1HPGD
SCHEMBL17438513 0.66 KDM5A (0.47) P2RX1ALDH1A1KDM4EMEN1HPGD
SCHEMBL352816 0.66 PARK7 (0.48) P2RX1ALDH1A1KDM4EMEN1HPGD
SCHEMBL17438626 0.65 P2RX1 (0.51) P2RX1ALDH1A1KDM4EMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP claimed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US claimed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US claimed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG P2RX1 3615/4885ALDH1A1 2365/4885KDM4E 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.